These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Discount for only one drug of the same group leads to impaired health care quality]. Bergström R Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044 [No Abstract] [Full Text] [Related]
11. Using a drug-safety tool to prevent competition. Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666 [No Abstract] [Full Text] [Related]
12. The impact of generic substitution on price competition in Finland. Aalto-Setälä V Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226 [TBL] [Abstract][Full Text] [Related]
13. Congress works to permit 'biosimilar' drugs very soon. Carroll J Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559 [No Abstract] [Full Text] [Related]
14. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
15. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers. Rea TS Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713 [No Abstract] [Full Text] [Related]
16. Generics battle brand names over mortality of drug patents. Betz R J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008 [No Abstract] [Full Text] [Related]
17. Prescription drugs and health care reform. Gibaldi M Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681 [No Abstract] [Full Text] [Related]
18. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing? Sturm AC Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287 [No Abstract] [Full Text] [Related]
19. The importance of being first: evidence from Canadian generic pharmaceuticals. Hollis A Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372 [TBL] [Abstract][Full Text] [Related]
20. The Hatch-Waxman Act: balancing competing interests or survival of the fittest? Behrendt KE Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990 [No Abstract] [Full Text] [Related] [Next] [New Search]